participating in a clinical trial to identify novel screening approaches for these patients. This screening program consists of whole-body MRI (including dedicated brain MRI), skin examination, urine cytology annually, and comprehensive laboratory studies
Search Results
Monique A. de Bruin, James M. Ford, and Allison W. Kurian
Therese B. Bevers, Mark Helvie, Ermelinda Bonaccio, Kristine E. Calhoun, Mary B. Daly, William B. Farrar, Judy E. Garber, Richard Gray, Caprice C. Greenberg, Rachel Greenup, Nora M. Hansen, Randall E. Harris, Alexandra S. Heerdt, Teresa Helsten, Linda Hodgkiss, Tamarya L. Hoyt, John G. Huff, Lisa Jacobs, Constance Dobbins Lehman, Barbara Monsees, Bethany L. Niell, Catherine C. Parker, Mark Pearlman, Liane Philpotts, Laura B. Shepardson, Mary Lou Smith, Matthew Stein, Lusine Tumyan, Cheryl Williams, Mary Anne Bergman, and Rashmi Kumar
imaging may include diagnostic mammography, ultrasonography, and at times diagnostic breast MRI. The eventual decision regarding need for tissue sampling is based on level of suspicion on imaging and/or clinical examination. Biopsy is needed in situations
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Vicki Keedy, Edward Kim, Henry Koon, Joel Mayerson, Martin McCarter, Sean V. McGarry, Christian Meyer, Zachary S. Morris, Richard J. O'Donnell, Alberto S. Pappo, I. Benjamin Paz, Ivy A. Petersen, John D. Pfeifer, Richard F. Riedel, Bernice Ruo, Scott Schuetze, William D. Tap, Jeffrey D. Wayne, Mary Anne Bergman, and Jillian L. Scavone
details about tumor size and contiguity to nearby visceral structures and neurovascular landmarks. The panel recommends MRI with contrast, with or without CT with contrast. Other imaging studies such as CT angiogram and plain radiograph may be warranted in
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
asymptomatic early-stage breast cancer. 10 In addition, monitoring of disease relapse with any tumor markers is not recommended. Use of MRI is optional and not universally recommended by experts in the field. Breast MRI advocates note its high sensitivity
David D. Buethe and Julio Pow-Sang
Reclassification Parameters Endorectal Multiparametric MRI Recently, a single-armed prospective trial 60 examined the efficacy of multiparametric T2-weighted endorectal MRI of the prostate with and without intravenous contrast. The accuracy of the
Parijatham S. Thomas
months. Screening with breast MRI was previously recommended for women with elevated risk for breast cancer predominately due to family history of breast cancer, but did not include those with history of AH or LCIS. 38 Due to insufficient evidence to
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz
clinical stage II/III rectal cancer (T3/4N1-2 based on endorectal ultrasound or MRI) who had been treated with initial chemotherapy followed by chemoradiation at MSKCC between 2007 and 2012. Patients were chosen based on the treating physician’s comfort
Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho
difficult to determine accurately without sufficient tumor tissue. Review by an experienced neuropathologist is highly recommended. In addition, a postoperative MRI scan, with and without contrast, should be obtained 24 to 72 hours after surgery to document
Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, and Susan Darlow
the estimated 5-year risk of developing breast cancer exceeds 1%, consistent with recommendations for the average-risk population. Likewise, breast MRI screening in these carriers should begin when the estimated 5-year risk of developing breast cancer
Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy
measured endoscopic distance given the variability in the use of distal landmarks to determine this measurement. Because endoscopic measurements of distance to the tumor can be misleading, pelvic imaging with CT, MRI, and endorectal ultrasound (EUS) can
